Ionis Pharmaceuticals, Inc. (IONS) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$102.29M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$117.42M; Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA (m); Operating income -$214.46M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$160.18M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$102.29M | (m) | $267.95M | (m) | $16.08M* | $565.53M* | $2.74M | (m) | $150.40M | $1.26M |
| 2026-03-31 | Reported | (m) | -$117.42M | (m) | $246.09M | (m) | $21.76M | -$792.82M | $2.98M | (m) | $150.36M | $218.00K |
| 2025-12-31 | Reported | (m) | -$214.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$160.18M | (m) | $156.72M | (m) | $5.27M* | -$131.44M* | $2.34M | (m) | $96.81M | $213.00K |
| 2025-06-30 | Reported | (m) | $139.82M | (m) | $452.05M | (m) | $12.30M* | $151.34M* | $4.15M | (m) | $90.62M | -$20.00K |
| 2025-03-31 | Reported | (m) | -$146.86M | (m) | $131.61M | (m) | $12.58M | -$150.78M | $1.46M | (m) | $76.25M | $116.00K |
| 2024-12-31 | Reported | (m) | -$110.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$148.66M | (m) | $133.81M | (m) | $9.06M* | -$114.99M* | $1.07M | (m) | $61.64M | -$3.62M |
| 2024-06-30 | Reported | (m) | -$66.09M | (m) | $225.25M | (m) | $6.23M* | -$119.88M* | $4.16M | (m) | $65.11M | $64.00K |
| 2024-03-31 | Reported | (m) | -$149.51M | (m) | $119.50M | (m) | $4.49M | -$149.94M | $2.15M | (m) | $52.64M | $75.00K |
| 2023-12-31 | Reported | (m) | -$6.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$143.26M | (m) | $144.21M | (m) | $2.14M* | -$109.02M* | $2.19M | (m) | $69.95M | $6.60M |
| 2023-06-30 | Reported | (m) | -$90.19M | (m) | $188.41M | (m) | $12.01M* | -$97.36M* | $2.54M | (m) | $46.14M | $7.84M |
| 2023-03-31 | Reported | (m) | -$114.15M | (m) | $130.52M | (m) | $10.47M | -$133.99M | $1.34M | (m) | $45.52M | $11.38M |
| 2022-12-31 | Reported | (m) | -$208.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$59.15M | (m) | $159.77M | (m) | $5.54M* | -$24.43M* | $1.51M | (m) | $34.42M | $283.00K |
| 2022-06-30 | Reported | (m) | -$85.51M | (m) | $133.79M | (m) | $3.33M* | -$18.10M* | $4.75M | (m) | $33.80M | $2.26M |
| 2022-03-31 | Reported | (m) | -$57.50M | (m) | $141.92M | (m) | $2.71M | -$31.65M | $4.17M | (m) | $34.13M | $1.09M |
| 2021-12-31 | Reported | (m) | $220.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$85.85M | (m) | $133.09M | (m) | $3.32M* | -$55.57M* | $3.08M | (m) | $31.09M | -$1.31M |
| 2021-06-30 | Reported | (m) | -$72.97M | (m) | $125.75M | (m) | $4.36M* | -$62.65M* | $2.96M | (m) | $56.45M | $327.00K |
| 2021-03-31 | Reported | (m) | -$91.97M | (m) | $111.61M | (m) | $1.77M | -$54.66M | $2.58M | (m) | $61.20M | $130.00K |
| 2020-12-31 | Reported | (m) | -$22.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$36.54M | (m) | $160.08M | (m) | $11.79M* | -$10.28M* | $3.09M | (m) | $68.45M | $5.06M |
| 2020-06-30 | Reported | (m) | -$51.75M | (m) | $145.54M | (m) | $9.10M* | -$44.22M* | $3.01M | (m) | $72.02M | $2.08M |
| 2020-03-31 | Reported | (m) | -$61.13M | (m) | $133.37M | (m) | $9.08M | -$7.59M | $2.55M | (m) | $74.99M | -$3.07M |
| 2019-12-31 | Reported | (m) | $260.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | (m) | $2.52M | (m) | $167.89M | (m) | $15.90M* | -$12.81M* | $967.00K | (m) | $60.04M | -$14.91M |
| 2019-06-30 | Reported | (m) | -$18.83M | (m) | $163.81M | (m) | $4.01M* | -$27.11M* | $1.36M | (m) | $75.11M | -$6.93M |
| 2019-03-31 | Reported | (m) | $121.53M | (m) | $297.21M | (m) | $3.23M | $107.70M | $1.04M | (m) | $68.22M | $31.05M |
| 2018-12-31 | Reported | (m) | $10.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$18.57M | (m) | $145.40M | (m) | $3.24M* | -$26.00M* | $0.00 | (m) | $68.71M | $452.00K |
| 2018-06-30 | Reported | (m) | -$50.28M | (m) | $117.75M | (m) | $6.63M* | $500.24M* | $0.00 | (m) | $66.20M | $358.00K |
| 2018-03-31 | Reported | (m) | -$3.30M | (m) | $144.42M | (m) | $2.34M | $13.16M | $0.00 | (m) | $43.65M | $15.00K |
| 2017-12-31 | Reported | (m) | -$6.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Reported | (m) | $11.31M | (m) | $118.31M | (m) | $17.05M* | $28.72M* | (m) | (m) | $26.79M | $961.00K |
| 2017-06-30 | Reported | (m) | $6.45M | (m) | $112.27M | (m) | $6.22M* | $2.36M* | (m) | (m) | $22.32M | $222.00K |
| 2017-03-31 | Reported | (m) | $19.48M | (m) | $115.80M | (m) | $3.24M | $122.67M | (m) | (m) | $13.68M | $0.00 |
| 2016-12-31 | Reported | (m) | $41.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Reported | (m) | $16.11M | (m) | (m) | (m) | $1.05M* | $24.29M* | (m) | (m) | $10.19M | $0.00 |
| 2016-06-30 | Reported | (m) | -$48.93M | (m) | (m) | (m) | $2.63M* | (m) | (m) | (m) | $9.82M | -$231.00K |
| 2016-03-31 | Reported | (m) | -$54.65M | (m) | (m) | (m) | $628.00K | (m) | (m) | (m) | $10.56M | $232.00K |
| 2015-12-31 | Reported | (m) | -$62.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$48.14M | (m) | (m) | (m) | $1.34M* | (m) | (m) | (m) | (m) | $0.00 |
| 2015-06-30 | Reported | (m) | $44.65M | (m) | (m) | (m) | $3.06M* | (m) | (m) | (m) | (m) | $789.00K |
| 2015-03-31 | Reported | (m) | -$9.33M | (m) | (m) | (m) | $878.00K | (m) | (m) | (m) | (m) | -$789.00K |
| 2014-12-31 | Reported | (m) | $10.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$21.49M | (m) | (m) | (m) | $869.00K* | (m) | (m) | (m) | (m) | $1.40M |
| 2014-06-30 | Reported | (m) | -$6.65M | (m) | (m) | (m) | $1.70M* | (m) | (m) | (m) | (m) | $881.00K |
| 2014-03-31 | Reported | (m) | -$29.67M | (m) | (m) | (m) | $1.40M | (m) | (m) | (m) | (m) | -$2.28M |
| 2013-12-31 | Reported | (m) | -$19.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$25.50M | (m) | (m) | (m) | $522.00K* | (m) | (m) | $45.00M | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$7.93M | (m) | (m) | (m) | $369.00K* | (m) | (m) | $42.63M | (m) | (m) |
| 2013-03-31 | Reported | (m) | $1.63M | (m) | (m) | (m) | $222.00K | (m) | (m) | $38.31M | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$26.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$28.05M | (m) | (m) | (m) | $169.00K* | -$24.87M* | (m) | $35.60M | (m) | -$706.00K |
| 2012-06-30 | Reported | (m) | $3.70M | (m) | (m) | (m) | $751.00K* | -$2.58M* | (m) | $40.44M | (m) | $0.00* |
| 2012-03-31 | Reported | (m) | -$18.45M | (m) | (m) | (m) | $113.00K | -$6.71M | (m) | $38.71M | (m) | $2.00K |
| 2011-12-31 | Reported | (m) | -$18.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$22.32M | (m) | (m) | (m) | $2.95M* | -$23.17M* | (m) | $39.92M | (m) | $0.00* |
| 2011-06-30 | Reported | (m) | -$14.06M | (m) | (m) | (m) | $3.41M* | -$26.18M* | (m) | $36.01M | (m) | $9.00K |
| 2011-03-31 | Reported | (m) | -$16.11M | (m) | (m) | (m) | $2.58M | -$39.84M | (m) | $34.24M | (m) | $2.00K |
| 2010-12-31 | Reported | (m) | -$15.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$8.95M | (m) | (m) | (m) | $846.00K* | -$21.43M* | (m) | $34.72M | (m) | $0.00* |
| 2010-06-30 | Reported | (m) | -$18.67M | (m) | (m) | (m) | $885.00K* | $5.03M* | (m) | $39.12M | (m) | $2.00K |
| 2010-03-31 | Reported | (m) | -$4.88M | (m) | (m) | (m) | $11.01M | -$21.69M | (m) | $31.99M | (m) | (m) |
| 2009-09-30 | Reported | (m) | -$10.40M | (m) | (m) | (m) | $1.45M* | -$32.26M* | (m) | $33.83M | (m) | $724.00K |
| 2009-06-30 | Reported | (m) | -$4.83M | (m) | (m) | (m) | (m) | (m) | (m) | $32.15M | (m) | -$11.00K |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Rolling | (m) | -$594.36M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | Rolling | (m) | -$352.25M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | Reported | (m) | -$381.68M | (m) | $943.71M | (m) | $51.44M | -$268.58M | $15.91M | $915.62M | $393.87M | $1.79M |
| 2025-12-31 | Rolling | (m) | -$381.69M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | Rolling | (m) | -$278.05M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | Rolling | (m) | -$266.52M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | Rolling | (m) | -$472.43M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$475.08M | (m) | $705.14M | (m) | $45.28M | -$500.95M | $11.21M | $901.53M | $267.47M | -$6.17M |
| 2024-12-31 | Rolling | (m) | -$475.08M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | Rolling | (m) | -$370.38M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | Rolling | (m) | -$364.99M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | Rolling | (m) | -$389.10M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$353.73M | (m) | $787.65M | (m) | $23.80M | -$307.51M | $9.13M | $899.63M | $232.62M | $32.32M |
| 2023-12-31 | Rolling | (m) | -$353.73M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | Rolling | (m) | -$555.63M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | Rolling | (m) | -$471.52M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | Rolling | (m) | -$466.83M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$410.19M | (m) | $587.37M | (m) | $15.72M | -$274.37M | $14.12M | (m) | $150.29M | $11.74M |
| 2022-12-31 | Rolling | (m) | -$410.19M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | Rolling | (m) | $18.43M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | Rolling | (m) | -$8.26M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | Rolling | (m) | $4.28M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$30.19M | (m) | $810.46M | (m) | $11.96M | $30.80M | $10.84M | $638.20M | $186.35M | -$551.00K |
| 2021-12-31 | Rolling | (m) | -$30.19M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | Rolling | (m) | -$273.45M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | Rolling | (m) | -$224.14M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | Rolling | (m) | -$202.93M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$172.08M | (m) | $729.26M | (m) | $35.12M | $35.89M | $11.95M | $531.00M | $354.32M | $345.19M |
| 2020-12-31 | Rolling | (m) | -$172.08M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | Rolling | (m) | $111.23M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | Rolling | (m) | $150.29M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | Rolling | (m) | $183.22M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | Reported | (m) | $365.88M | (m) | $1.12B | (m) | $30.91M | $345.63M | $4.38M | $461.50M | $286.64M | $51.51M |
| 2019-12-31 | Rolling | (m) | $365.88M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Rolling | (m) | $116.01M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | $94.92M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | $63.46M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$61.37M | (m) | $599.67M | (m) | $13.61M | $602.91M | $1.82M | $411.90M | $244.62M | -$291.14M |
| 2018-12-31 | Rolling | (m) | -$61.37M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$78.35M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$48.47M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | Rolling | (m) | $8.26M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | $31.05M | (m) | $514.18M | (m) | $34.76M | $174.15M | $0.00 | $372.50M | $108.49M | -$5.98M |
| 2017-12-31 | Rolling | (m) | $31.05M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Rolling | (m) | $78.40M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | Rolling | (m) | $83.20M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | Rolling | (m) | $27.82M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$20.16M | (m) | $372.78M | (m) | $7.11M | -$112.11M | $0.00 | $340.40M | $48.62M | $2.93M |
| 2016-12-31 | Rolling | (m) | -$46.32M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Rolling | (m) | -$150.41M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | Rolling | (m) | -$214.66M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | Rolling | (m) | -$121.08M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$75.76M | (m) | (m) | (m) | $7.69M | $21.13M | (m) | $319.50M | $37.17M | $372.00K |
| 2015-12-31 | Rolling | (m) | -$75.76M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Rolling | (m) | -$2.74M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | Rolling | (m) | $23.90M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | Rolling | (m) | -$27.39M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$47.73M | (m) | (m) | (m) | $7.52M | (m) | (m) | $238.90M | (m) | -$15.41M |
| 2014-12-31 | Rolling | (m) | -$47.73M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | Rolling | (m) | -$77.67M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | Rolling | (m) | -$81.68M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | Rolling | (m) | -$82.96M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$51.67M | (m) | (m) | (m) | $1.55M | (m) | (m) | $173.70M | (m) | -$5.91M |
| 2013-12-31 | Rolling | (m) | -$51.67M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | Rolling | (m) | -$57.93M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | Rolling | (m) | -$60.47M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | Rolling | (m) | -$48.84M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$68.92M | (m) | (m) | (m) | $1.48M | (m) | (m) | $154.60M | (m) | -$9.11M |
| 2012-12-31 | Rolling | (m) | -$68.92M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | Rolling | (m) | -$61.42M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | Rolling | (m) | -$55.69M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | Rolling | (m) | -$73.45M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | Reported | (m) | -$71.10M | (m) | (m) | (m) | $10.20M | -$114.80M | (m) | $153.10M | (m) | $11.00K |
| 2011-12-31 | Rolling | (m) | -$71.10M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | Rolling | (m) | -$68.34M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | Rolling | (m) | -$54.97M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | Rolling | (m) | -$59.58M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | Reported | (m) | -$48.36M | (m) | (m) | (m) | $13.24M | -$63.59M | (m) | $145.16M | (m) | $92.00K |
| 2010-12-31 | Rolling | (m) | -$48.36M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | Reported | (m) | -$27.54M | (m) | (m) | (m) | $13.41M | -$108.44M | (m) | $134.62M | (m) | $3.19M |
| 2008-12-31 | Reported | (m) | -$13.06M | (m) | (m) | (m) | $13.66M | $212.03M | (m) | $106.44M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |